Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

CAR Tregs targeting OX40L for GvHD

December 16, 2024 8:44 PM UTC

CAR Treg cells targeting OX40L, a T cell-activating costimulatory signal upregulated in GvHD, could help treat GVHD by suppressing alloreactive T effector cells.

A CAR construct that combined a single-chain variable fragment targeting human OX40L with intracellular CD28 costimulatory and CD3 signaling domains was transduced into activated human Treg cells to generate OX40L-targeting CAR T reg cells...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Boston Children's Hospital

BCIQ Target Profiles

OX40 ligand (OX40L) (CD134L)